{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:50:36Z","timestamp":1792590636248,"version":"4.5.0"},"reference-count":34,"publisher":"MyJove Corporation","issue":"232","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/70644","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:00:59Z","timestamp":1781132459000},"source":"Crossref","is-referenced-by-count":0,"title":["Retrospective Comparative Study of Tacrolimus and Cyclophosphamide Treatment in Pediatric Lupus Nephritis"],"prefix":"10.3791","author":[{"given":"Qinna","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40272-023-00609-3","type":"journal-article","article-title":"Managing lupus nephritis in children and adolescents","volume":"26","author":"Chan","year":"2023","unstructured":"Chan, E. Y.-h. et al. Managing lupus nephritis in children and adolescents. Pediatr Drugs. 26 (2), 145-161 (2023).","journal-title":"Pediatr Drugs"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00467-024-06654-5","type":"journal-article","article-title":"The unique challenges of childhood-onset systemic lupus erythematosus and lupus nephritis patients: a proposed framework for an individualized transitional care plan","volume":"40","author":"Renson","year":"2025","unstructured":"Renson, T., Lightstone, L., Ciurtin, C., Gaymer, C., Marks, S. D. The unique challenges of childhood-onset systemic lupus erythematosus and lupus nephritis patients: a proposed framework for an individualized transitional care plan. Pediatr Nephrol. 40 (10), 3045-3053 (2025).","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-025-01128-w","type":"journal-article","article-title":"Prognostic factors for disease progression and mortality of childhood-onset lupus nephritis in the Philippines: a retrospective cohort study in a tertiary hospital","volume":"23","author":"Asis","year":"2025","unstructured":"Asis, C. M. L., Tee, C. A., Resontoc, L. P. R. Prognostic factors for disease progression and mortality of childhood-onset lupus nephritis in the Philippines: a retrospective cohort study in a tertiary hospital. Pediatr Rheumatol. 23 (1), 86 (2025).","journal-title":"Pediatr Rheumatol"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/s-0043-1768168","type":"journal-article","article-title":"Clinicopathological, immunological, and laboratory parameters of childhood lupus nephritis: a study from Northeast India","volume":"15","author":"Das","year":"2023","unstructured":"Das, J. et al. Clinicopathological, immunological, and laboratory parameters of childhood lupus nephritis: a study from Northeast India. J Lab Physicians. 15 (3), 361-364 (2023).","journal-title":"J Lab Physicians"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"106937","DOI":"10.1016\/j.imlet.2024.106937","type":"journal-article","article-title":"Could tolerance to DNA be broken in the gut in systemic lupus erythematosus","volume":"270","author":"Spencer","year":"2024","unstructured":"Spencer, J., Jain, S. Could tolerance to DNA be broken in the gut in systemic lupus erythematosus? Immunol Lett. 270, 106937 (2024).","journal-title":"Immunol Lett"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/B978-0-12-814551-7.00035-0","type":"journal-article","article-title":"Mechanisms of renal damage in systemic lupus erythematosus","author":"Fu","year":"2021","unstructured":"Fu, S. M., Sung, S.-S. J., Wang, H., Zhao, Z., Gaskin, F. Mechanisms of renal damage in systemic lupus erythematosus. Syst Lupus Erythematosus. 313-324 (2021).","journal-title":"Syst Lupus Erythematosus"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/art.40155","type":"journal-article","article-title":"Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis","volume":"69","author":"Fu","year":"2017","unstructured":"Fu, R. et al. Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. Arthritis Rheumatol. 69 (8), 1636-1646 (2017).","journal-title":"Arthritis Rheumatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"595672","DOI":"10.3389\/fimmu.2020.595672","type":"journal-article","article-title":"Vasculature-associated lymphoid tissue: a unique tertiary lymphoid tissue correlates with renal lesions in lupus nephritis mouse model","volume":"11","author":"Masum","year":"2020","unstructured":"Masum, M. A. et al. Vasculature-associated lymphoid tissue: a unique tertiary lymphoid tissue correlates with renal lesions in lupus nephritis mouse model. Front Immunol. 11, 595672 (2020).","journal-title":"Front Immunol"},{"issue":"3","key":"ref9","first-page":"313","type":"journal-article","article-title":"Update and clinical management of anti-DNA auto-antibodies","volume":"2","author":"Gonz\u00e1lez Rodr\u00edguez","year":"2021","unstructured":"Gonz\u00e1lez Rodr\u00edguez, C., Aparicio Hern\u00e1ndez, M. B., Alarc\u00f3n Torres, I. Update and clinical management of anti-DNA auto-antibodies. Adv Lab Med. 2 (3), 313-321 (2021).","journal-title":"Adv Lab Med"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"e001708","DOI":"10.1136\/lupus-2025-001708","type":"journal-article","article-title":"Significant glomerular IgM deposition predicts poorer kidney outcomes in lupus nephritis compared with other forms of immune complex deposits","volume":"12","author":"Xiang","year":"2025","unstructured":"Xiang, W. et al. Significant glomerular IgM deposition predicts poorer kidney outcomes in lupus nephritis compared with other forms of immune complex deposits. Lupus Sci Med. 12 (2), e001708 (2025).","journal-title":"Lupus Sci Med"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejr.2020.01.001","type":"journal-article","article-title":"Treatment response and progression to end stage renal disease in adolescents and young adults with lupus nephritis: a follow up study in an Egyptian cohort","volume":"42","author":"Abdulrahman","year":"2020","unstructured":"Abdulrahman, M. A., Sallam, D. E. Treatment response and progression to end stage renal disease in adolescents and young adults with lupus nephritis: a follow up study in an Egyptian cohort. Egypt Rheumatol. 42 (3), 189-193 (2020).","journal-title":"Egypt Rheumatol"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semarthrit.2019.03.010","type":"journal-article","article-title":"Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus","volume":"49","author":"Deng","year":"2019","unstructured":"Deng, J., Chalhoub, N. E., Sherwin, C. M., Li, C., Brunner, H. I. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 49 (2), 251-259 (2019).","journal-title":"Semin Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0165-5728(92)90144-A","type":"journal-article","article-title":"Macrophages and the glucocorticoids","volume":"40","author":"Russo-Marie","year":"1992","unstructured":"Russo-Marie, F. Macrophages and the glucocorticoids. J Neuroimmunol. 40, 281-286 (1992).","journal-title":"J Neuroimmunol"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"e14569","DOI":"10.1016\/j.heliyon.2023.e14569","type":"journal-article","article-title":"Natural product-driven dual COX-LOX inhibitors: overview of recent studies on the development of novel anti-inflammatory agents","volume":"9","author":"Mukhopadhyay","year":"2023","unstructured":"Mukhopadhyay, N., Shukla, A., Makhal, P. N., Kaki, V. R. Natural product-driven dual COX-LOX inhibitors: overview of recent studies on the development of novel anti-inflammatory agents. Heliyon. 9 (3), e14569 (2023).","journal-title":"Heliyon"},{"issue":"15","key":"ref15","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.3390\/ijms20153714","type":"journal-article","article-title":"Potential prognostic markers of acute kidney injury in the early phase of acute pancreatitis","volume":"20","author":"Wajda","year":"2019","unstructured":"Wajda, J. et al. Potential prognostic markers of acute kidney injury in the early phase of acute pancreatitis. Int J Mol Sci. 20 (15), 3714 (2019).","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"622225","DOI":"10.3389\/fmed.2021.622225","type":"journal-article","article-title":"The use of glucocorticoids in lupus nephritis: new pathways for an old drug","volume":"8","author":"Mej\u00eda-Vilet","year":"2021","unstructured":"Mej\u00eda-Vilet, J. M., Ayoub, I. The use of glucocorticoids in lupus nephritis: new pathways for an old drug. Front Med. 8, 622225 (2021).","journal-title":"Front Med"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40629-020-00127-5","type":"journal-article","article-title":"Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches","volume":"29","author":"G\u00fclsen","year":"2020","unstructured":"G\u00fclsen, A., Wedi, B., Jappe, U. Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches. Allergo J Int. 29 (5), 139-154 (2020).","journal-title":"Allergo J Int"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.braindev.2023.11.008","type":"journal-article","article-title":"Neuropsychiatric manifestations associated with juvenile systemic lupus erythematosus: an overview focusing on early diagnosis","volume":"46","author":"Nikolaidou","year":"2024","unstructured":"Nikolaidou, A., Beis, I., Dragoumi, P., Zafeiriou, D. Neuropsychiatric manifestations associated with juvenile systemic lupus erythematosus: an overview focusing on early diagnosis. Brain Dev. 46 (3), 125-134 (2024).","journal-title":"Brain Dev"},{"issue":"S12","key":"ref19","doi-asserted-by":"crossref","first-page":"SI180","DOI":"10.1093\/rheumatology\/keae264","type":"journal-article","article-title":"Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study","volume":"63","author":"Zhang","year":"2024","unstructured":"Zhang, L. et al. Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study. Rheumatology. 63 (S12), SI180-SI187 (2024).","journal-title":"Rheumatology"},{"issue":"3-4","key":"ref20","doi-asserted-by":"crossref","first-page":"c165","DOI":"10.1159\/000346149","type":"journal-article","article-title":"Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice","volume":"121","author":"Tanaka","year":"2013","unstructured":"Tanaka, H. et al. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice. Nephron Clin Pract. 121 (3-4), c165-173 (2013).","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0961203317719148","type":"journal-article","article-title":"Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan","volume":"27","author":"Sakai","year":"2017","unstructured":"Sakai, R. et al. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan. Lupus. 27 (2), 273-282 (2017).","journal-title":"Lupus"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1081-1206(10)62636-1","type":"journal-article","article-title":"Tacrolimus (FK 506)","volume":"83","author":"Letko","year":"1999","unstructured":"Letko, E., Bhol, K., Pinar, V., Foster, C. S., Ahmed, A. R. Tacrolimus (FK 506). Ann Allergy Asthma Immunol. 83 (3), 179-190 (1999).","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1089-3261(02)00029-6","type":"journal-article","article-title":"Evolving new therapies of autoimmune hepatitis","volume":"6","author":"Vierling","year":"2002","unstructured":"Vierling, J. M., Flores, P. A. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis. 6 (3), 825-850 (2002).","journal-title":"Clin Liver Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"101798","DOI":"10.1016\/j.trim.2023.101798","type":"journal-article","article-title":"Infections after organ transplantation and immune response","volume":"77","author":"Elalouf","year":"2023","unstructured":"Elalouf, A. Infections after organ transplantation and immune response. Transpl Immunol. 77, 101798 (2023).","journal-title":"Transpl Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/651803","type":"journal-article","article-title":"Successful treatment with mycophenolate mofetil and tacrolimus in juvenile severe lupus nephritis","volume":"2015","author":"Kise","year":"2015","unstructured":"Kise, T., Yoshimura, H., Fukuyama, S., Uehara, M. Successful treatment with mycophenolate mofetil and tacrolimus in juvenile severe lupus nephritis. Case Rep Pediatr. 2015, 1-4 (2015).","journal-title":"Case Rep Pediatr"},{"issue":"1194","key":"ref26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/postmj\/qgae181","type":"journal-article","article-title":"The 2024 revision of the Declaration of Helsinki: a modern ethical framework for medical research","volume":"101","author":"Wen","year":"2025","unstructured":"Wen, B., Zhang, G., Zhan, C., Chen, C., Yi, H. The 2024 revision of the Declaration of Helsinki: a modern ethical framework for medical research. Postgrad Med J. 101 (1194), 371-382 (2025).","journal-title":"Postgrad Med J"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","type":"journal-article","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","unstructured":"Hochberg, M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40 (9), 1725 (1997).","journal-title":"Arthritis Rheum"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.12669\/pjms.38.5.5117","type":"journal-article","article-title":"Analysis of the safety and efficacy of tacrolimus combined with glucocorticoid in the treatment of lupus nephritis","volume":"38","author":"Li","year":"2022","unstructured":"Li, L., Du, Y., Ji, J., Gao, Y., Shi, X. Q. Analysis of the safety and efficacy of tacrolimus combined with glucocorticoid in the treatment of lupus nephritis. Pak J Med Sci. 38 (5), 1285-1291 (2022).","journal-title":"Pak J Med Sci"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.jid.2017.08.007","type":"journal-article","article-title":"Research techniques made simple: choosing appropriate statistical methods for clinical research","volume":"137","author":"Kim","year":"2017","unstructured":"Kim, N., Fischer, A. H., Dyring-Andersen, B., Rosner, B., Okoye, G. A. Research techniques made simple: choosing appropriate statistical methods for clinical research. J Invest Dermatol. 137 (10), e173-e178 (2017).","journal-title":"J Invest Dermatol"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1007\/s00431-024-05662-9","type":"journal-article","article-title":"Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis","volume":"183","author":"Li","year":"2024","unstructured":"Li, H., Chen, C., Yang, H., Tu, J. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis. Eur J Pediatr. 183 (9), 3987-3995 (2024).","journal-title":"Eur J Pediatr"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","type":"journal-article","article-title":"2024 American College of Rheumatology guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","unstructured":"Sammaritano, L. R. et al. 2024 American College of Rheumatology guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. 77 (9), 1115-1135 (2025).","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1177\/09612033251361560","type":"journal-article","article-title":"Comparative efficacy of intravenous cyclophosphamide, mycophenolate mofetil, and tacrolimus as induction therapy for lupus nephritis: a randomized controlled open-label trial","volume":"34","author":"Amudalapalli","year":"2025","unstructured":"Amudalapalli, A. et al. Comparative efficacy of intravenous cyclophosphamide, mycophenolate mofetil, and tacrolimus as induction therapy for lupus nephritis: a randomized controlled open-label trial. Lupus. 34 (12), 1211-1220 (2025).","journal-title":"Lupus"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1439781","DOI":"10.3389\/fphar.2024.1439781","type":"journal-article","article-title":"Signal detection and analysis of adverse events associated with Genvoya based the FAERS database","volume":"15","author":"Wang","year":"2024","unstructured":"Wang, C., Zhang, Y., Tang, X., Zhang, G., Chen, L. Signal detection and analysis of adverse events associated with Genvoya based the FAERS database. Front Pharmacol. 15, 1439781 (2024).","journal-title":"Front Pharmacol"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.64229\/2ew2fm31","type":"journal-article","article-title":"Targeting IL-17A: a new frontier in the treatment of colitis-associated cancer","volume":"1","author":"Pandurangan","year":"2025","unstructured":"Pandurangan, A. K. Targeting IL-17A: a new frontier in the treatment of colitis-associated cancer. Curr Cancer Res. 1 (1), 16-25 (2025).","journal-title":"Curr Cancer Res"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/70644\/retrospective-comparative-study-tacrolimus-cyclophosphamide-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:33:31Z","timestamp":1792589611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/70644\/retrospective-comparative-study-tacrolimus-cyclophosphamide-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":34,"journal-issue":{"issue":"232","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/70644","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}